Refractive and visual outcomes with posterior chamber implantable phakic contact lens (IPCL) for presbyopia patients: one-year follow-up

Session Details

Session Title: Posterior Chamber Phakic IOLs

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 15:46

Venue: Free Paper Forum: Podium 3

First Author: : M.Tomita JAPAN

Co Author(s): :                                 

Abstract Details

Purpose:

To evaluate refractive and visual outcomes following presbyopia correcting implantable phakic contact lens (IPCL) implantation. IPCL are single piece posterior chamber phakic IOLs, made from hybrid hydrophilic acrylic material. Presbyopia correcting diffractive IPCL interacts with the crystalline lens to enhance patient’s residual accommodation.

Setting:

Minoru Tomita Eye Clinic, Tokyo, Japan

Methods:

This study included 238 eyes of 119 patients who had undergone bilateral implantation of presbyopia correcting IPCL (Eyeol, UK). The main outcome measures included Uncorrected Distance Visual Acuity (UDVA) and Uncorrected Near Visual Acuity (UNVA), Corrected Distance Visual Acuity (CDVA) and Corrected Near Visual Acuity (CNVA) and manifest refraction (sphere, cylinder and spherical equivalent (SE)). Patients were examined preoperatively and 1, 3, 6 and 12 months postoperatively.

Results:

Mean age of the subjects was 50±5 years old. At post-operative 1 month, UDVA, UNVA and refraction were significantly improved from preoperative values (p < 0.05). Preoperatively, the mean SE of -3.79D was reduced to -0.22D at 1 month and was found to be stable throughout the follow up period of 12 months. Mean preoperative UDVA was 20/125, which was improved to 20/20 at 1 year visit, with no significant change in CDVA. Correspondingly, UNVA was improved from J7 to J1 and CNVA was remained stable over the 12 months. No intraoperative or postoperative complications were observed.

Conclusions:

Implantation of IPCL for the correction of presbyopia is safe and effective, with good visual and refractive outcomes. Results were found to be stable until the last follow up visit at 12 months.

Financial Disclosure:

None